 |  |
| ABX | ||
| 971.476 | ||
| 11.9610 | 0.0125% | |
| BISNIS-27 | ||
| 510.460 | ||
| -1.8610 | -0.0036% | |
| DBX | ||
| 1,941.157 | ||
| 6.3100 | 0.0033% | |
| ECONOMIC30 | ||
| 116.726 | ||
| -0.2770 | -0.0024% | |
| ESGQKEHATI | ||
| 123.097 | ||
| -0.3690 | -0.0030% | |
| ESGSKEHATI | ||
| 122.710 | ||
| -0.4710 | -0.0038% | |
| I-GRADE | ||
| 201.772 | ||
| -0.4370 | -0.0022% | |
| AUDRP | ||
| 10,143.000 | ||
| -24.9000 | -0.2449% | |
| EURRP | ||
| 16,882.200 | ||
| -9.0000 | -0.0533% | |
| JPYRP | ||
| 103.696 | ||
| 0.1640 | 0.1584% | |
| SINRP | ||
| 11,944.800 | ||
| -23.8000 | -0.1989% | |
| USDRP | ||
| 16,190.000 | ||
| -110.0000 | -0.6748% | |
Kandidat obat oral untuk pasien COVID-19 bertambah dengan kehadiran pil antivirus Paxlovid. Berdasarkan hasil sementara uji klinis fase II/III, Paxlovid menunjukkan hasil yang baik sehingga segera diajukan untuk mendapatkan izin penggunaan darurat.
